Menbutone/Genabilic acid pharma-grade API for tablet, capsule, granule, and injection applications is supplied as the free carboxylic acid, systematically named 4-(4-methoxynaphthalen-1-yl)-4-oxobutanoic acid, CAS 3563-14-2, molecular formula C15H14O4, relative molecular mass 258.27 g/mol. The product is released in four grade models: MBT-O/M micronized oral grade, MBT-O/G granulation-direct oral grade, MBT-I/L low-endotoxin injectable grade, and MBT-I/S sterile injectable API. As a synthetic choleretic, the substance is used in veterinary medicinal products for hepatobiliary and digestive support; the free acid is preferred for solid oral forms because it is crystalline and non-hygroscopic, whereas injectable formulations require controlled in situ salt formation. Unlike phytogenic choleretics, menbutone is a single chemical entity with defined crystalline, chromatographic, and thermal specifications, permitting impurity control and quantitative release testing.

Production-scale manufacture is conducted under ICH Q7 in stainless steel reactors. The synthetic pathway is based on Friedel-Crafts acylation of an appropriate methoxynaphthalene intermediate with succinic anhydride, followed by hydrolytic workup and crystallization from isopropanol/water. This route generates impurity markers that are tracked in the related substances method, including the unreacted methoxynaphthalene intermediate and succinate ester derivatives. Commercial batches are typically produced at 50–100 kg scale. After vacuum drying, residual isopropanol is controlled below 2,000 ppm.

What Pharmacopoeial Acceptance Limits Govern Menbutone API Identity and Purity?

Identity is confirmed by infrared spectroscopy against a certified reference standard and by retention time agreement in the HPLC assay. The material is a white to off-white crystalline powder with a melting point reported near 172 °C to 174 °C. A dedicated menbutone monograph is not present in all major pharmacopoeias; therefore the release specification is built from Ph. Eur. general methods and ICH Q3C/Q3D provisions. Solubility is pH-dependent: the free acid is practically insoluble in purified water at 25 °C, soluble in dilute sodium hydroxide, and sparingly soluble in ethanol. Assay by anhydrous HPLC is controlled at 98.0–102.0%. Related substances limits are total impurities ≤0.5% with no single unidentified impurity exceeding 0.10%. Water content by Karl Fischer titration is ≤0.5% for oral grades and ≤0.3% for injectable grade material. Sulfated ash is ≤0.1%. Heavy metals are controlled to ≤10 ppm according to Ph. Eur. 2.4.8. Residual solvents are controlled under ICH Q3C; ethanol, methanol, isopropanol, and dichloromethane are monitored with limits derived from class 2 and class 3 solvent tables. The low-endotoxin injectable grade is released with a bacterial endotoxin limit derived from the intended maximum dose; a control point of ≤0.5 EU/mg is applied when the maximum target species dose is 10 mg/kg and testing is performed according to Ph. Eur. 2.6.14.

Particle-Size Control and Blend Uniformity in Menbutone Tablet and Capsule Granulation

For solid oral dosage forms, the micronized oral grade MBT-O/M is specified with laser diffraction D90 ≤75 µm and D50 ≤30 µm. The granulation-direct grade MBT-O/G is specified with D90 ≤180 µm to reduce electrostatic adhesion during low-shear mixing. Powder flow measured by Ph. Eur. 2.9.36 shows Carr index values of 25–35 for the unmilled free acid; after roller compaction at 2.0–3.5 kN/cm roll force, granulation-direct material typically falls to 15–20. Direct compression of the micronized grade is feasible only below 30,000 tablets/h on rotary presses with forced feeders; above this speed, capping and lamination occur because the acicular crystal habit of unmilled API generates anisotropic stress relaxation. Blends with lactose monohydrate and microcrystalline cellulose at API loads of 20–30% w/w provide acceptable content uniformity. When API load exceeds 40% w/w, bimodal particle size distribution can cause segregation during bin transfer; sampling thief data across 10 positions should be evaluated. Jet milling under nitrogen above 6 bar is not recommended if product temperature exceeds 40 °C, because surface amorphization increases water uptake by 0.2–0.4% and accelerates related substance formation.

Formulation of injectable menbutone solutions requires conversion of the free acid to the sodium salt by stoichiometric titration with sodium hydroxide or use of a suitable alkalizing agent. At pH >7.5, the carboxylate species yields clear aqueous solutions. A representative preparation for a 100 mg/mL injection uses the acid equivalent, sodium hydroxide to pH 8.0–8.5, water for injection, and optionally sodium metabisulfite 0.05–0.10% w/v as antioxidant. Terminal sterilization by autoclaving at 121 °C for 15 minutes is possible if solution pH remains above 7.8; below this pH, free acid precipitation and heat-induced degradation of the ketone side chain may increase. Aseptic filtration through 0.22 µm polyethersulfone filters is recommended for thermolabile formulations; adsorption losses are typically below 2% after discarding the first 500 mL filtrate. The resulting sodium salt solution at 25 °C shows viscosity of 1.1–1.5 mPa·s, suitable for 18-gauge needles. Finished solution particulate matter is assessed according to USP <788> for large-volume injectables and Ph. Eur. 2.9.19 for small-volume parenterals, with control limits of ≤25 particles/mL at ≥10 µm and ≤3 particles/mL at ≥25 µm. The free acid API is not sterile; sterile filtration or terminal sterilization is performed during finished-product manufacture.

Veterinary target species include cattle, sheep, horses, pigs, and companion animals; specific dosages are defined in the applicable veterinary medicinal product authorizations. Oral granules for feed incorporation typically use the API adsorbed onto lactose at 10–20% w/w active loading. Tablets of 100 mg, 250 mg, and 500 mg strengths and capsules of 100 mg and 200 mg are common solid oral formats. Injectable solutions are commonly formulated at 100 mg/mL after sodium salt formation and are intended for intramuscular or subcutaneous administration. Intravenous administration requires additional control of osmolality and pH because concentrated alkaline menbutone solutions can be locally irritating.

When Menbutone Is Selected Instead of Bile Acid Derivatives or Phytogenic Choleretics

Menbutone differs from ursodeoxycholic acid and other bile acid derivatives because it is not a micelle-forming detergent. It does not require emulsification or lipid co-solvents in parenteral formulations and does not produce the same degree of erythrocyte membrane perturbation in concentrated solutions. Compared with silymarin extract, menbutone is a single low-molecular-weight entity with a defined melting point and no polyphenolic auto-oxidation sensitivity; silymarin requires assay normalization to total flavonolignans and shows batch-to-batch variation in monomer ratios. Compared with dehydrocholic acid, menbutone has a different oxidation state and aromatic naphthalenone substitution, which alters salt-forming behavior and partitioning characteristics.

Stability Boundaries for Genabilic Acid Under Thermal and Humidity Stress

The free acid is chemically stable as a dry crystalline powder at 25 °C/60% RH for at least 36 months when stored in double polyethylene bags inside a fiber drum. Accelerated testing at 40 °C/75% RH for 6 months shows related substances below 0.5% and assay within 98.0–102.0%. Storage above 60% RH without desiccant can increase water content by 0.3–0.7%, promoting hydrolysis of the ketone side chain. The compound should not be micronized under high-humidity air because amorphous surface layers absorb water and cause caking and loss of flow. Incompatibilities are observed with strong reducing agents, which can reduce the ketone group, and with primary amine-based excipients under aqueous alkaline conditions, where Schiff base formation may occur. Oxidative degradation is limited but can be accelerated by trace iron and copper ions; EDTA or citrate is recommended in aqueous injectable formulations at 0.01–0.05% w/v.

What Equipment Parameters Prevent Sticking and Capping in Menbutone Tablet Compression?

Tablet compression of menbutone oral formulations requires control of punch coating and granulation moisture. On a 27-station rotary tablet press with compaction force 8–14 kN and turret speed 25–35 rpm, capping increases if granule moisture is below 1.5% w/w. Moisture between 2.0% and 3.0% w/w reduces elastic recovery after compression. Sticking to steel punches is observed with magnesium stearate levels above 1.5% w/w; the recommended lubricant level is 0.5–1.0% w/w, with extended mixing limited to 3 minutes at 15 rpm to avoid hydrophobization. The tableting environment is maintained at 20–25 °C and 35–45% RH. For capsule filling, direct filling of MBT-O/G into hard gelatin capsules on a dosator machine requires granule bulk density of 0.45–0.55 g/mL; tamping force above 150 N can compact the granule and reduce dissolution. Granule preparation by fluid-bed top-spray with binder solution containing 5% povidone K30 and 2% croscarmellose sodium produces granules with Hausner ratio below 1.25.

Batch release testing for the API includes reversed-phase HPLC using a C18 column, 150 mm × 4.6 mm, 5 µm particle size, column temperature 30 °C, injection volume 10 µL, mobile phase acetonitrile and 0.1% phosphoric acid, flow rate 1.0 mL/min, and UV detection at 254 nm. System suitability requires theoretical plates above 2,000 and tailing factor below 2.0. Forced degradation studies show that the molecule is most sensitive to alkaline hydrolysis and oxidation; the main degradation product 4-methoxynaphthalene-1-carboxylic acid is resolved at relative retention time 0.45. The limit of quantitation for this degradation product is 0.05% and the detection limit is 0.02%. Oral-grade microbial limits conform to Ph. Eur. 5.1.4 category 3B: total aerobic microbial count ≤10³ CFU/g, total yeast and mold count ≤10² CFU/g, absence of Escherichia coli in 1 g. Injectable grade is tested for sterility according to Ph. Eur. 2.6.1 after membrane filtration; sterility assurance is achieved at finished-product level unless sterile API is specifically procured.

Cleaning validation for equipment contact surfaces uses swab sampling with HPLC detection. The acceptance limit for menbutone residue is derived from the permitted daily exposure and maximum daily dose of the next product; in a shared veterinary API line the cleaning limit is typically 10 ppm or the calculated permitted daily exposure, whichever is lower. Because the free acid is ionized above pH 7.5, wash solutions containing 0.1 M sodium hydroxide improve recovery from stainless steel. Dry residue is removed with alkaline detergent followed by water rinses, and the molecule is not volatile, so residue assessment focuses on surface swabbing rather than air monitoring.